We narrowed to 307 results for: cha

#213833-AAV5

Ready-to-use AAV5 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213829-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_dTomato_nlsdTomato (#213829). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213830-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_ChR2_mCherry (#213830). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213830-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiCHATe27_ChR2_mCherry (#213830). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213829-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiCHATe27_dTomato_nlsdTomato (#213829). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213833-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 29, 2025

Academic Institutions and Nonprofits only

#139505-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Oct. 28, 2021

Academic Institutions and Nonprofits only

#139505-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#139504-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

April 10, 2024

Academic Institutions and Nonprofits only

#139504-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Nov. 13, 2025

Academic Institutions and Nonprofits only

#230681-AAV5

Ready-to-use AAV5 particles produced from AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA (#230681). In addition to the viral particles, you will also receive purified AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA plasmid DNA. minBG-driven expression of iCre recombinase in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 6, 2025

Academic Institutions and Nonprofits only

#117382-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#117382-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Oct. 28, 2021

Academic Institutions and Nonprofits only

#117382-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Feb. 14, 2022

Academic Institutions and Nonprofits only

#104055-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

June 13, 2023

Academic Institutions and Nonprofits only

#117382-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#117382-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Aug. 15, 2025

Academic Institutions and Nonprofits only

#104055-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Sept. 27, 2023

Academic Institutions and Nonprofits only

#163509-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP11839-pAAV-hSyn1-SYFP2-10aa-H2B-WPRE3-BGHpA (Alias: CN1839) (#163509). In addition to the viral particles, you will also receive purified AiP11839-pAAV-hSyn1-SYFP2-10aa-H2B-WPRE3-BGHpA (Alias: CN1839) plasmid DNA. hSyn1-driven expression for nuclear SYFP2 labeling in neurons. Useful for nuclear isolation and scRNA-seq applications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 17, 2022

Academic Institutions and Nonprofits only